Posted on 2017-04-01
Myeloma cancer leukemia cancer cells
There are big expectations for big sales over time for Johnson & Johnson multiple myeloma drug Darzalex: nearly $5 billion by 2022. But England's drug price watchdog is making it hard on J&J to realize its potential there. In draft guidance issued today Janssen said it is extremely concerned that the National Institute for Health and Care Excellence (NICE) has not recommended Darzalex for treatment of relapsed and refractory multiple myeloma in adults in preliminary guidelines.
Non-profit organization featuring research, clinical trials, events, fundraising and a newsletter. The prognosis of multiple myeloma is usually based on the existence of different signs, symptoms, and circumstances. Multiple prognosis as well as Multiple myeloma is a cancer that arises from a type of white blood cells called plasma cells. Therefore, most patients with have immunoglobulin protein, called Bence-Jones protein, in their urine. In these patients, there is no protein in the bloo